Diabetes Therapy

U.S. FDA approves NovoLog for treatment of diabetes in children

Published in Obesity and Diabetes Week, October 10th, 2005

Novo Nordisk, Inc., announced that the U.S. Food & Drug Administration (FDA) has approved the supplemental new drug application of NovoLog (insulin aspart [rDNA origin] injection) for the treatment of diabetes in children.

NovoLog is a rapid-acting insulin analogue which can be administered immediately before a meal. The FDA approval comes approximately 4 months before the agency's review deadline.

"The incidence of both type 1 and type 2 diabetes is increasing in children," said Peter Aurup, MD, vice president of clinical development, medical, and regulatory affairs, Novo Nordisk, Inc. "Approximately 1 in every 400-500 children and adolescents has...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry